Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Meets Expectations

Key Points

• Theravance Biopharma reported quarterly EPS of $0.07, matching analysts’ consensus estimate. The company posted an 18.84% return on equity and a 104.34% net margin.
• TBPH opened at $16.93, with a market capitalization of approximately $872.5 million and a 12-month trading range of $11.20 to $21.03. Analysts maintain a consensus “Hold” rating and a $19.40 price target.
• Insiders sold 350,011 shares worth roughly $6.0 million over the past 90 days, while institutional investors and hedge funds own 99.10% of the stock.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) posted its earnings results on Monday. The biopharmaceutical company reported $0.07 earnings per share for the quarter, meeting the consensus estimate of $0.07, Zacks reports. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%.

Theravance Biopharma Price Performance

TBPH opened at $16.93 on Monday. The stock has a market capitalization of $872.48 million, a PE ratio of 7.70 and a beta of 0.19. Theravance Biopharma has a 12-month low of $11.20 and a 12-month high of $21.03. The firm's fifty day moving average price is $16.77 and its 200 day moving average price is $16.91.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. HC Wainwright downgraded shares of Theravance Biopharma from a "buy" rating to a "neutral" rating and raised their price objective for the stock from $15.00 to $17.00 in a research report on Tuesday, July 7th. JonesTrading downgraded Theravance Biopharma from a "buy" rating to a "hold" rating in a report on Monday, June 29th. Wall Street Zen lowered Theravance Biopharma from a "buy" rating to a "hold" rating in a research note on Saturday, May 16th. Weiss Ratings raised Theravance Biopharma from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, August 3rd. Finally, Zacks Research cut Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a report on Monday, June 8th. Eight equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $19.40.

Insider Activity

In other Theravance Biopharma news, SVP Rhonda Farnum sold 13,314 shares of the company's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the sale, the senior vice president owned 232,457 shares in the company, valued at $3,809,970.23. This represents a 5.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 273,871 shares of the business's stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $17.23, for a total value of $4,718,797.33. Following the completion of the sale, the insider owned 9,237,279 shares of the company's stock, valued at $159,158,317.17. This trade represents a 2.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 350,011 shares of company stock worth $6,008,309 in the last ninety days. Corporate insiders own 7.65% of the company's stock.

Institutional Investors Weigh In On Theravance Biopharma

Several large investors have recently added to or reduced their stakes in TBPH. Quarry LP bought a new position in shares of Theravance Biopharma during the third quarter worth about $26,000. Caitong International Asset Management Co. Ltd grew its position in Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company's stock worth $40,000 after purchasing an additional 1,411 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock valued at $55,000 after buying an additional 781 shares during the last quarter. CIBC Private Wealth Group LLC boosted its position in shares of Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company's stock worth $68,000 after buying an additional 4,662 shares during the period. Finally, AQR Capital Management LLC bought a new position in Theravance Biopharma in the 1st quarter worth approximately $101,000. 99.10% of the stock is owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source